Challenges and considerations in interpreting the age-dependent benefit of neoadjuvant treatment for adenocarcinoma of the esophagus and gastroesophageal junction-Reference-Cited by-同舟云学术

Challenges and considerations in interpreting the age-dependent benefit of neoadjuvant treatment for adenocarcinoma of the esophagus and gastroesophageal junction

Published:2024-05-10 Issue:9 Volume:110 Page:5837-5840
ISSN:1743-9159
Container-title:International Journal of Surgery
language:en
Short-container-title:

Author:

Li Kexun¹,Yan Hongchi²,Ke Tengfei¹³

Affiliation:

1. Department of Thoracic Surgery I, Key Laboratory of Lung Cancer of Yunnan Province, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province

2. Changning County Traditional Chinese Medicine Hospital, Yibin, China

3. Department of Radiology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference23 articles.

1. Age-dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction: a multicenter retrospective observational study of young versus old patients;Rompen;Int J Surg,2023

2. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial;Shapiro;Lancet Oncol,2015

3. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE);Yan;Int J Surg,2022

4. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial;Yang;J Clin Oncol,2018

5. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer;Kelly;New Engl J Med,2021